Business Wire

TRM Labs Acquires UK Crypto Investigations Training Company CSITech

13.6.2022 19:32:00 EEST | Business Wire | Press release

Share

Today, TRM Labs, the blockchain intelligence company, announced the acquisition of CSITech, a global leader in crypto and blockchain investigative training. CSITech adds its nearly two decades of investigative training experience to TRM’s suite of compliance tools and service offerings for crypto business, government and law enforcement agency, and financial institution clientele.

CSITech, a UK-based firm, delivers in-person and online training on blockchain and cryptocurrency investigations. CSITech is widely recognized as the leading crypto investigations training firm and has trained international law enforcement bodies at all levels on investigative techniques and best practices for investigating cryptocurrency-related crimes.

“TRM is on a mission to bring trust and safety to the crypto economy. Providing first-rate tools and training to law enforcement and compliance professionals that help safeguard this ecosystem is a core component,” said Esteban Castaño, co-founder and CEO of TRM Labs. “We’re excited about the expanded training capabilities Nick and his team of experts will allow us to offer to our global base of customers.”

CSITech’s expertise will augment and expand TRM’s existing portfolio of training services, which includes TRM Academy – an extensive library of self-serve digital courses available to all TRM customers as a complimentary resource – and several multi-day certification courses designed to advance the skills of professionals ranging compliance practitioners who are new to crypto to experienced crypto investigators.

“We’re committed to delivering the best training and certifications to our students, clients and partners in pursuit of our tireless mission to see the crypto space become a safer and more trustworthy environment for all,” said Nick Furneaux, Managing Director at CSITech.

“The pro level courses we are delivering are for those with a high existing knowledge base, who have taken a number of existing courses available and are looking to acquire the techniques and skills to take their capabilities, services offerings and careers to the next level.”

Mr. Furneaux is an internationally renowned expert of blockchain forensics and author of Investigating Cryptocurrencies: Understanding, Extracting, and Analyzing Blockchain Evidence (2018). In 18 years of operation, CSITech established itself as the preeminent crypto investigations training provider with top law enforcement agents among its alumni. Former pupils are currently leading some of the most well known cryptocurrency investigations in the sector, including cases involving hacks against exchanges, organized crime groups and sanctions evasion.

“Since 2019, TRM Labs has constantly innovated to build a blockchain investigations tool for today’s crypto ecosystem. We at CSITech are thrilled to join TRM on its mission to build a safer financial system for billions of people and expand our capability to train the next generation of leading cryptocurrency investigators,” said Furneaux. He and other CSITech personnel join TRM’s Training and Certifications team, operating in close collaboration with TRM’s Global Investigations team led by former IRS-Criminal Investigations (IRS-CI) Special Agent Chris Janczewski, who joined TRM in March 2022.

“The cryptocurrency space is evolving at tremendous pace and requires investigators and industry leaders to educate and prepare to match the industry’s scale,” said Chris Janczewski, Head of Global Investigations for TRM. “My team and I work closely with TRM’s Training and Certifications program to ensure that the course material continues to reflect the reality of the job on the ground.”

TRM’s certifications portfolio includes a range of multi-day course offerings that can be delivered virtually or in-person: TRM Crypto Fundamentals Certification (TRM-CFC), TRM Certified Crypto Compliance Specialist (TRM-CCS), TRM Certified Investigator (TRM-CI) and TRM Advanced Crypto Investigator (TRM-ACI). For more information and to enquire about booking group or individual courses, visit the TRM website here.

About TRM Labs

TRM provides blockchain intelligence to help financial institutions, cryptocurrency businesses and public agencies detect, investigate and manage crypto-related fraud and financial crime. TRM's risk management platform includes solutions for cryptocurrency anti-money laundering (AML), transaction monitoring and wallet screening, entity risk scoring including Know-Your-VASP, and transaction tracing for investigations. These tools enable a rapidly growing cohort of organizations around the world to safely embrace cryptocurrency-related transactions, products, and partnerships. TRM is based in San Francisco, CA and is hiring across engineering, product, sales, and data science. To learn more, visit www.trmlabs.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media:
Rachel Saulpaugh
trm-labs@wachsman.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye